St. Luke's University Health Network, headquartered in Bethlehem, Pennsylvania, is a non-profit network of 12 hospitals and over 300 outpatient sites. The health network has over 16,000 employees.

There are 480 beds in Saint Luke's University Hospital-Bethlehem Campus.

During the past decade, Saint Luke's University Hospital-Bethlehem Campus conducted 50 clinical trials. In the 10-year time frame, 50 clinical trials started and 72 clinical trials were completed, i.e. on average, 144% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 39 clinical trials were completed. i.e. 487.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Saint Luke's University Hospital-Bethlehem Campus" #1 sponsor was "National Cancer Institute (NCI)" with 54 trials, followed by "Alliance for Clinical Trials in Oncology" with 8 trials sponsored, "Gynecologic Oncology Group" with 7 trials sponsored, "GOG Foundation" with 6 trials sponsored and "Bristol-Myers Squibb" with 6 trials sponsored. Other sponsors include 49 different institutions and companies that sponsored additional 43 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Saint Luke's University Hospital-Bethlehem Campus" #1 collaborator was "National Cancer Institute (NCI)" with 34 trials as a collaborator, "NRG Oncology" with 18 trials as a collaborator, "Canadian Cancer Trials Group" with 5 trials as a collaborator, "Cancer and Leukemia Group B" with 5 trials as a collaborator and "NCIC Clinical Trials Group" with 5 trials as a collaborator. Other collaborators include 63 different institutions and companies that were collaborators in the rest 59 trials.

According to Clinical.Site data, the most researched conditions in "Saint Luke's University Hospital-Bethlehem Campus" are "Ovarian Seromucinous Carcinoma" (8 trials), "Recurrent Fallopian Tube Carcinoma" (8 trials), "Recurrent Ovarian Carcinoma" (8 trials), "Fallopian Tube Transitional Cell Carcinoma" (7 trials) and "Ovarian Serous Adenocarcinoma" (7 trials). Many other conditions were trialed in "Saint Luke's University Hospital-Bethlehem Campus" in a lesser frequency.

Most popular intervention types in "Saint Luke's University Hospital-Bethlehem Campus" are "Drug" (90 trials), "Other" (73 trials), "Biological" (43 trials), "Procedure" (22 trials) and "Radiation" (21 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (39 trials), "Quality-of-Life Assessment" (34 trials), "Paclitaxel" (25 trials), "Carboplatin" (20 trials) and "Bevacizumab" (16 trials). Other intervention names were less common.

The vast majority of trials in "Saint Luke's University Hospital-Bethlehem Campus" are 93 trials for "All" genders, 35 trials for "Female" genders and 5 trials for "Male" genders.

Currently, there are NaN active trials in "Saint Luke's University Hospital-Bethlehem Campus". undefined are not yet recruiting, 12 are recruiting, 52 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 50 completed trials in Saint Luke's University Hospital-Bethlehem Campus, 1 suspended trials, and 11 terminated clinical trials to date.

Out of the total trials that were conducted in Saint Luke's University Hospital-Bethlehem Campus, 4 "Phase 1" clinical trials were conducted, 36 "Phase 2" clinical trials and 72 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 15 trials that are defined as “Not Applicable".

Saint Luke's University Hospital-Bethlehem Campus has several departments that took part in Clinical trials: "St. Luke's Hospital Cancer Center" - 73 trials, "St. Luke's Cancer Network at St. Luke's Hospital" - 31 trials, "Sacred Heart Hospital" - 11 trials